Abstract :Liver transplantation remains the only definitive treatment for end-stage liver disease. With only 6000 donor livers available each year nationally, the need far exceeds the supply. Innovative cell-based therapies, such as hepatic tissue engineering, offer alternatives to supplement the limited supply of quality organs for transplantation.